XERS Form 4: Option Exercise at $6.66 and Weighted Sale at $7.92
Rhea-AI Filing Summary
Jeffrey W. Sherman, a director of Xeris Biopharma Holdings, Inc. (XERS), reported insider transactions on 08/28/2025. He exercised a stock option to acquire 47,040 shares at an exercise price of $6.66 and, on the same date, sold 42,232 shares at a weighted-average price of $7.9209. After these transactions he beneficially owned 219,188 shares directly and an additional 5,400 shares indirectly through the Jeffrey W Sherman Living Trust, for a disclosed total of 224,588 shares reported on this Form 4. The option exercised was originally granted in 2016 (assumed in an acquisition) and vests fully; the option grant underlying the exercised shares shows an expiration date of 10/01/2026.
Positive
- Exercised vested options to acquire 47,040 shares at an exercise price of $6.66
- Disclosed indirect trust holdings of 5,400 shares (Jeffrey W Sherman Living Trust)
Negative
- Sold 42,232 shares at a weighted-average price of $7.9209, reducing direct holdings
- Net change in direct reported shares shows a decrease from 261,420 to 219,188 after transactions
Insights
TL;DR: Director exercised options for 47,040 shares at $6.66 and sold 42,232 shares at ~$7.92 on 08/28/2025; net direct holdings remain substantial.
The reporting shows a routine exercise-and-partial-sale transaction: the director converted vested options into shares and disposed of a portion at a weighted-average price of $7.9209. The filings disclose remaining direct ownership of 219,188 shares and an indirect 5,400 shares in a trust. These are straightforward Section 16 transactions with no additional compensatory or novel financing terms reported.
TL;DR: Transactions are standard for insiders exercising vested options and selling shares; disclosures appear complete and properly signed.
The Form 4 identifies the reporting person as a director and provides required details: transaction codes, amounts, prices (weighted average for sales), and a trust disclosure for indirect holdings. The form includes the reporting attorney-in-fact signature and an explanation of the option origin. No amendments or flags are present in the visible document.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 47,040 | $0.00 | -- |
| Exercise | Common Stock | 47,040 | $6.66 | $313K |
| Sale | Common Stock | 42,232 | $7.9209 | $335K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.920 to $7.935, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. On October 1, 2016, the reporting person was granted an option to purchase shares of Strongbridge Biopharma plc ("Strongbridge") which were assumed by Issuer in connection with the acquisition of Strongbridge. The options vested in full on October 5, 2021.
